inovirusassoci
vector
iav
engin
nonlyt
filament
bacteriophag
assembl
primarili
thousand
copi
major
coat
protein
five
copi
four
minor
coat
protein
inoviru
display
studi
shown
architectur
inovirus
make
coat
protein
inovir
particl
access
outsid
particular
featur
iav
allow
foreign
antigen
peptid
display
outer
surfac
virion
fuse
coat
protein
two
decad
exploit
mani
applic
includ
antibodi
peptid
display
librari
drug
design
vaccin
develop
infecti
noninfecti
diseas
vaccin
carrier
iav
shown
elicit
cellular
humor
respons
variou
pathogen
display
antibodi
epitop
coat
protein
despit
high
immunogen
goal
develop
effect
vaccin
yet
materi
one
possibl
limit
previou
effort
use
broadli
neutral
antibodi
exhibit
autoreact
properti
past
five
year
howev
new
potent
broadli
neutral
antibodi
exhibit
autoreact
properti
isol
infect
individu
suggest
vaccin
strategi
aim
produc
broadli
neutral
antibodi
may
confer
protect
infect
util
new
broadli
neutral
antibodi
combin
architectur
trait
iav
driven
current
develop
design
inovirusbas
vaccin
virus
articl
review
applic
iav
vaccin
develop
particular
emphasi
design
inoviralbas
vaccin
filament
bacteri
virus
group
threadlik
virus
contain
singlestrand
dna
genom
collect
constitut
genu
inoviru
famili
inovirida
term
deriv
greek
word
filament
commonli
call
filament
bacteriophag
differ
known
individu
speci
filament
virus
major
capabl
infect
gramneg
bacteria
complex
interact
filament
phage
bacteri
host
specifi
receptor
organel
usual
encod
transmiss
plasmid
one
intrigu
featur
inovirus
assembl
host
membran
major
capsid
protein
subunit
replac
singlestrand
dna
bind
protein
progeni
virion
continu
extrud
medium
without
kill
infect
cell
give
rise
titer
virion
per
millilit
liquid
cultur
high
viru
product
associ
mild
retard
host
growth
give
rise
format
opaqu
plaqu
bacteri
lawn
sens
filament
virus
bear
resembl
symbiot
nonpathogen
anim
virus
rather
phage
term
come
greek
word
destroy
inoviru
virion
flexibl
slender
cylindr
filament
less
nm
diamet
order
nm
length
see
detail
figur
virion
sever
thousand
ident
major
capsid
coat
protein
subunit
packag
circular
singlestrand
dna
molecul
virion
also
specif
minor
protein
end
one
end
proxim
end
attach
infect
end
distal
end
nucleat
initi
assembl
process
host
membran
number
speci
inoviru
isol
character
differ
part
world
rather
larg
among
e
coli
inovirus
beststudi
mostexploit
ff
group
close
relat
virus
fd
review
see
infect
male
f
strain
e
coli
ff
almost
ident
dna
protein
sequenc
gene
organ
structur
paramet
fd
differ
genom
posit
nucleotid
fd
nucleotid
genet
life
cycl
three
virus
fd
studi
extens
know
great
deal
ff
genom
contain
ten
tightli
arrang
gene
noncod
intergen
region
contain
packag
signal
origin
dna
replic
major
rhodepend
transcript
termin
recent
review
see
five
ten
viral
gene
encod
protein
found
virion
gene
found
proxim
end
virion
essenti
infect
stabil
wherea
gene
gene
protein
respect
locat
distal
end
virion
respons
initi
assembl
endtoend
model
illustr
figur
proxim
distal
minor
coat
protein
subunit
maintain
fivefold
axial
symmetri
major
coat
protein
subunit
along
virion
life
cycl
ff
filament
virus
start
adsorpt
viru
tip
f
specif
pilu
e
coli
attach
take
place
mean
adsorpt
structur
compos
five
copi
locat
proxim
end
virion
see
figur
mainli
sequenti
bind
domain
tip
f
pilu
domain
periplasm
domain
iii
tola
recent
review
see
refer
adsorpt
viru
drawn
surfac
cell
major
coat
protein
subunit
becom
associ
inner
membran
cell
circular
singlestrand
dna
cssdna
releas
cytoplasm
insid
cytoplasm
cssdna
convert
parent
doublestrand
replic
form
rf
ff
inovirus
replic
genom
rollingcircl
mechan
consecut
transcript
rf
dna
translat
well
asymmetr
singl
strand
dna
synthesi
lead
intracellular
pool
viral
precursor
complex
contain
viral
singlestrand
dna
molecul
bound
protein
subunit
except
small
hairpin
loop
serv
packag
signal
virion
assembl
major
coat
protein
subunit
synthes
signal
peptid
sequenc
facilit
transport
insert
bacteri
membran
cleav
signal
peptidas
cleavag
matur
coat
protein
left
span
membran
c
terminu
cytoplasm
n
terminu
outsid
cytoplasm
periplasm
assembl
filament
virus
take
place
membran
subunit
replac
subunit
first
step
assembl
sequenc
bind
packag
signal
site
nucleotid
form
hairpin
loop
presum
five
subunit
minor
coat
protein
viru
assembl
proce
singlestrand
dna
pass
membran
matur
coat
protein
subunit
ad
entir
dna
molecul
packag
distal
end
virion
five
copi
ad
complet
virion
releas
medium
assembl
inovirus
bacteri
inner
membran
harmon
sequenti
process
involv
varieti
interact
viralencod
protein
hostencod
protein
without
kill
host
bacterium
review
structur
ff
viru
extens
studi
number
laboratori
last
five
decad
howev
despit
effort
structur
complet
determin
critic
question
remain
unansw
major
difficulti
virus
crystal
orient
fiber
suitabl
xray
fiber
diffract
studi
crystal
interpret
fiber
diffract
pattern
togeth
number
physicochem
measur
shown
major
coat
protein
subunit
fivestart
helic
symmetri
rotat
axi
refer
class
strictli
base
fundament
symmetri
protein
subunit
helic
determin
fiber
diffract
review
hand
structur
packag
ssdna
molecul
virion
includ
helic
symmetri
interact
protein
sheath
one
least
understood
aspect
structur
dna
insid
virus
determin
convent
xray
fiber
diffract
techniqu
partli
low
dna
content
virion
theoret
studi
demonstr
singlestrand
dna
molecul
uniqu
packag
insid
ff
virion
predomin
electrostat
interact
scale
schemat
model
endtoend
ff
fd
inovir
virion
model
base
publish
physic
data
includ
determin
helic
paramet
major
coat
protein
xray
structur
domain
minor
coat
protein
model
show
rel
locat
circular
singlestrand
dna
cssdna
genom
nucleotid
long
illustr
blue
ribbon
structur
detail
outer
virion
capsid
major
coat
protein
four
minor
coat
protein
present
end
virion
top
digit
scan
transmiss
electron
micrograph
stem
unstain
fd
viru
prepar
wetfilm
techniqu
accord
previous
establish
procedur
brookhaven
stem
facil
end
one
complet
virion
design
arrow
data
collect
collabor
la
day
j
wall
brookhaven
nation
laboratori
upton
new
york
stem
condit
fd
virion
long
diamet
middl
propos
endtoend
scale
diagram
fd
virion
present
entir
fd
virion
compos
subunit
except
two
end
architectur
detail
axial
slab
long
virion
length
consist
entir
subunit
major
coat
protein
structur
extend
shown
surfac
ribbon
imag
present
virion
model
cylindr
stack
gray
disk
long
diamet
imag
deriv
coordin
rcsb
pdb
databas
access
number
use
pymol
subunit
arrang
helic
symmetri
includ
twofold
screw
axi
fivefold
rotat
axi
consist
two
pentam
two
pentam
architectur
relat
translat
along
virion
axi
rotat
axi
proxim
end
virion
shown
left
compos
five
copi
minor
coat
protein
recent
review
see
proxim
end
model
base
partial
inform
known
structur
specif
ntermin
portion
model
follow
helic
paramet
base
protein
sequenc
homolog
two
five
copi
subunit
model
base
structur
inform
domain
imag
domain
shown
deriv
coordin
rcsb
pdb
databas
access
number
use
pymol
domain
organ
also
shown
distal
end
virion
right
consist
five
copi
minor
coat
protein
model
follow
helic
paramet
accord
previous
publish
model
easi
genet
manipul
inovirus
possibl
insert
random
oligonucleotid
genom
set
foundat
inoviru
display
phage
display
technolog
express
genet
modifi
inovirus
result
present
oligopeptid
fusion
protein
surfac
virion
herein
term
iav
inovirusassoci
vector
iav
modifi
express
oligopeptid
either
copi
particular
capsid
protein
one
possibl
insert
oligonucleotid
sequenc
interest
viral
genom
creat
fusion
capsid
protein
oligopeptid
display
everi
copi
capsid
protein
altern
phagemid
vector
use
carri
extra
copi
capsid
protein
oligonucleotid
fuse
coinfect
bacteri
host
phagemid
vector
replic
defici
helper
phage
carri
wild
type
capsid
protein
would
result
mosaic
inoviru
particl
contain
copi
wild
type
coat
protein
recombin
protein
contain
oligopeptid
interest
nonmosa
mosaic
iav
display
peptid
recent
review
iav
display
peptid
review
elsewher
contrast
fourcapsid
protein
capsid
protein
util
product
mosaic
virion
figur
illustr
display
antigen
five
capsid
protein
iav
indic
publish
literatur
also
introduc
new
terminolog
denot
gene
oligopeptid
fuse
whether
virion
mosaic
display
mani
copi
oligopeptid
iav
ideal
capsid
protein
util
result
nonmosa
iav
display
peptid
approxim
copi
capsid
surfac
tradeoff
howev
signific
limit
size
peptid
peptid
amino
acid
may
display
without
distort
assembl
viru
see
figur
size
restrict
display
peptid
may
overcom
gener
mosaic
iav
display
foreign
peptid
minor
viral
surfac
regard
display
peptid
possibl
mosaic
iav
present
even
whole
protein
viral
surfac
although
case
protein
expect
present
five
copi
per
virion
studi
show
virion
carri
none
one
copi
protein
surfac
random
peptid
librari
rpl
one
common
applic
iav
random
oligopeptid
display
differ
clone
inoviru
particl
vast
divers
rpl
depend
size
oligopeptid
complex
rpl
increas
exponenti
size
oligopeptid
increas
rpl
subsequ
use
mani
applic
includ
identif
peptid
ligand
receptor
map
substrat
site
enzym
creation
antibodi
peptid
librari
applic
review
elsewher
inoviru
display
technolog
also
use
epitop
map
vaccin
design
purpos
rpl
use
character
epitop
antibodi
interest
biopan
monoclon
antibodi
interest
result
isol
mimotop
oligopeptid
mimic
nativ
antibodi
epitop
select
recombin
inovirus
carri
mimotop
isol
order
determin
dna
amino
acid
sequenc
display
oligopeptid
dna
sequenc
insert
well
structur
predict
analysi
potenti
identifi
previous
unknown
target
antibodi
besid
antibodi
character
inocul
recombin
inovirus
isol
approach
potenti
use
vaccin
carrier
exampl
neutral
antibodi
pathogen
use
screen
rpl
select
peptid
fuse
inovirus
would
mimic
origin
antibodi
epitop
vaccin
anim
inovirus
could
ultim
induc
product
similar
antibodi
vaccin
individu
offer
protect
infect
pathogen
inoviru
display
technolog
success
appli
develop
vaccin
variou
pathogen
tabl
potenti
inoviru
display
technolog
facilit
map
antibodi
epitop
great
import
especi
case
epitop
broadli
neutral
monoclon
antibodi
could
rare
vulner
spot
surfac
frequent
mutat
viru
therefor
identif
studi
could
lead
new
drug
therapi
vaccin
target
review
focus
particularli
applic
inoviru
display
technolog
util
capsid
protein
use
vaccin
develop
schemat
represent
antigen
display
surfac
ff
inovirusassoci
vector
iav
foreign
antigen
shown
red
sphere
design
left
denot
inovir
gene
genet
modifi
express
antigen
outer
architectur
virion
iav
contain
wild
type
antigen
display
capsid
protein
design
indic
virion
mosaic
ff
virion
contain
copi
major
capsid
protein
five
copi
minor
capsid
protein
inovirusassoci
vector
bottom
show
major
coat
protein
subunit
arrang
combin
fivefold
rotat
axi
approxim
twofold
screw
axi
right
correspond
surfac
lattic
ident
previous
publish
lattic
diagram
show
rel
posit
subunit
outer
virion
surfac
five
subunit
two
interlock
pentam
constitut
helic
symmetri
virion
indic
blue
green
dot
respect
rel
virion
surfac
area
associ
subunit
mark
yellow
virion
perimetr
azimuthi
distanc
calcul
base
virion
diamet
display
antigen
repres
red
sphere
arrang
surfac
inovirusassoci
vector
accord
helic
symmetri
virion
outer
architectur
bottom
iav
effect
vaccin
carrier
shown
tabl
use
success
numer
vaccin
develop
studi
util
develop
vaccin
wide
varieti
viral
protozoan
worm
parasit
also
noninfecti
diseas
like
alzheim
variou
type
cancer
attempt
divid
two
main
subcategori
first
subcategori
inoviru
display
technolog
use
screen
rpl
monoclon
antibodi
select
immunogen
peptid
interest
select
peptid
use
vaccin
solubl
form
conjug
carrier
protein
second
subcategori
similar
first
subcategori
inoviru
display
technolog
use
epitop
map
isol
case
inovirus
also
use
vaccin
carrier
immunogen
peptid
contrast
iav
solubl
peptid
disadvantag
less
stabl
peptid
fuse
inovir
particl
solubl
peptid
flexibl
structur
thu
alway
retain
structur
desir
epitop
result
solubl
peptid
unlik
inovirusbound
peptid
less
capabl
induc
product
desir
antibodi
addit
inovir
vector
display
peptid
highli
immunogen
high
immunogen
reinforc
abil
inovirus
display
multipl
copi
peptid
surfac
addit
inovirus
known
structur
simplic
allow
immun
system
focu
select
display
peptid
viral
carrier
furthermor
sinc
inovirus
replic
e
coli
cultur
cost
vaccin
product
low
summari
iav
use
effici
cost
effect
vaccin
carrier
larg
number
research
studi
focus
applic
inovirusbas
vaccin
infecti
diseas
common
approach
mani
effort
vaccin
anim
inovirus
challeng
specif
pathogen
order
assess
level
protect
pathogen
three
studi
focus
immun
viral
parasit
bastien
et
al
fuse
linear
epitop
human
respiratori
syncyti
viru
rsv
glycoprotein
g
inoviru
use
recombin
inoviru
vaccin
mice
result
specif
humor
respons
vaccin
anim
complet
protect
challeng
rsv
viru
grabowska
et
al
use
monoclon
antibodi
herp
simplex
viru
type
glycoprotein
screen
rpl
select
recombin
inovirus
use
vaccin
mice
result
specif
humor
respons
high
surviv
rate
vaccin
mice
challeng
lethal
dose
viru
observ
level
protect
proport
dose
inovir
vaccin
addit
yu
et
al
use
monoclon
antibodi
surfac
glycoprotein
neurotrop
murin
coronaviru
screen
variou
rpl
select
clone
display
peptid
induc
humor
immun
respons
cellular
respons
mice
even
lethal
viru
challeng
three
six
mice
surviv
besid
viral
infect
inovir
vaccin
research
also
appli
system
candidiasi
fungal
infect
caus
candida
albican
two
separ
studi
specif
six
amino
acid
peptid
epitop
fungal
heat
shock
protein
display
fusion
inovir
coat
protein
infect
parasit
mice
immun
recombin
inovirus
fewer
coloni
form
unit
candida
albican
kidney
longer
lifespan
use
inoviru
vaccin
carrier
particularli
success
taenia
solium
parasit
worm
use
pig
intermedi
host
caus
neurocysticercosi
parasit
diseas
central
nervou
system
human
manoutsarian
et
al
fuse
four
antigen
peptid
inovirus
cocktail
recombin
inovirus
use
vaccin
pig
result
specif
cellular
respons
induc
vaccin
pig
protect
challeng
pathogen
pig
total
protect
reduc
number
cysticerci
base
result
largescal
vaccin
rural
pig
villag
central
mexico
conduct
immun
success
sinc
vaccin
confer
signific
protect
parasit
furthermor
inovirusbas
vaccin
econom
compar
anoth
vaccin
made
synthet
peptid
studi
particularli
import
due
larg
scale
vaccin
attempt
inovirus
also
due
effect
significantli
reduc
number
cysticerci
vaccin
anim
effort
also
made
develop
vaccin
worm
schistosoma
japonicum
tang
et
al
screen
rpl
polyclon
serum
infect
mice
select
recombin
inovirus
induc
specif
humor
respons
confer
partial
protect
parasit
challeng
vaccin
mice
follow
studi
wang
et
al
use
monoclon
antibodi
target
parasit
screen
rpl
recombin
inovirus
induc
humor
cellular
respons
significantli
protect
vaccin
mice
worm
infect
addit
wu
et
al
use
polyclon
serum
infect
rabbit
screen
rpl
humor
respons
induc
vaccin
mice
confer
partial
protect
parasit
villamancera
et
al
produc
vaccin
fasciola
hepatica
screen
previous
construct
inoviru
rlp
anticathepsin
l
monoclon
antibodi
although
immun
sheep
select
recombin
inovirus
induc
weak
specif
humor
respons
challeng
parasit
vaccin
anim
remark
reduct
worm
burden
compar
control
inovirusbas
vaccin
construct
parasit
worm
trichinella
spirali
case
gu
et
al
use
monoclon
antibodi
antigen
screen
rpl
result
humor
respons
induc
vaccin
mice
gain
partial
protect
challeng
parasit
summari
result
studi
show
construct
effici
inovirusbas
vaccin
confer
protect
vaccin
anim
infecti
pathogen
achiev
induct
humor
cellular
immun
respons
previous
mention
inoviru
display
technolog
also
use
design
vaccin
noninfecti
diseas
case
capabl
vaccin
limit
progress
diseas
evalu
fang
et
al
display
epitop
melanoma
antigen
mage
surfac
inoviru
fuse
result
induct
cellular
immun
respons
melanoma
tumor
signific
inhibit
tumor
growth
vaccin
mice
addit
import
increas
surviv
rate
vaccin
anim
similar
result
obtain
wu
et
al
effort
design
vaccin
murin
mastocytoma
epitop
tumor
antigen
fuse
inovir
surfac
vaccin
mice
gain
signific
protect
tumor
growth
moreov
signific
increas
surviv
rate
due
antitumor
cellular
respons
induc
import
effort
also
made
design
inovirusbas
vaccin
alzheim
diseas
main
target
vaccin
induct
antibodi
plaqu
studi
antigen
epitop
display
inovir
surfac
epitop
egfr
consist
four
amino
acid
e
g
f
r
part
peptid
mice
immun
recombin
inovirus
research
observ
reduct
plaqu
burden
specif
humor
respons
collect
studi
show
possibl
protect
vaccin
anim
diseas
progress
thu
allud
promis
use
vaccin
noninfecti
diseas
human
summari
util
inovir
vector
vaccin
develop
infecti
noninfecti
diseas
produc
signific
promis
result
first
major
case
vaccin
success
sinc
induc
specif
humor
cellular
respons
furthermor
mani
case
attempt
evalu
efficaci
vaccin
challeng
pathogen
vaccin
anim
case
vaccin
could
provid
partial
signific
even
complet
protect
pathogen
establish
effect
use
inovirus
vaccin
vector
knowledg
neutral
epitop
initi
isol
sever
neutral
monoclon
antibodi
describ
thu
far
neutral
monoclon
antibodi
found
target
four
major
epitop
envelop
glycoprotein
monoclon
antibodi
target
mper
epitop
monoclon
antibodi
pgt
glycan
depend
site
loop
site
monoclon
antibodi
target
surfac
glycan
outer
domain
distinct
four
major
epitop
target
site
describ
inoviru
display
technolog
also
appli
vaccin
strategi
howev
unlik
success
develop
vaccin
parasit
effort
fail
publish
studi
see
tabl
inovirusdisplay
vaccin
made
util
broadli
neutral
antibodi
first
studi
construct
vaccin
use
inoviru
display
technolog
perform
keller
et
al
use
monoclon
antibodi
screen
rpl
vaccin
select
recombin
inovirus
rabbit
result
induct
typespecif
neutral
antibodi
year
later
zwick
et
al
use
monoclon
antibodi
screen
varieti
linear
constrain
rpl
howev
vaccin
mice
rabbit
select
recombin
inovirus
result
product
antibodi
detect
level
antibodi
use
dorgham
et
al
order
screen
rpl
select
mimotop
fuse
capsid
inovirus
use
vaccin
mice
induc
antibodi
could
bind
neutral
potenc
anoth
studi
wilkinson
et
al
screen
constrain
librari
antibodi
case
select
mimotop
fuse
small
heat
shock
protein
hsp
archeaon
methanococcu
jannaschii
carrier
protein
follow
vaccin
hspmimotop
rabbit
antibodi
without
neutral
potenc
produc
antibodi
use
first
time
menendez
et
al
screen
varieti
linear
constrain
rpl
nevertheless
vaccin
select
inovirus
rabbit
induc
product
antibodi
could
bind
recent
rodriguez
et
al
use
antibodi
screen
constrain
rpl
vaccin
mice
rabbit
led
product
nonneutr
antibodi
studi
use
inovir
vector
result
induct
specif
humor
respons
howev
sera
vaccin
anim
broadli
neutral
abil
besid
monoclon
antibodi
polyclon
sera
patient
also
use
screen
rpl
tabl
approach
carri
degre
uncertainti
sinc
base
premis
polyclon
sera
contain
least
one
broadli
neutral
monoclon
antibodi
mean
new
neutral
epitop
isol
rpl
suggest
longterm
nonprogressor
patient
remain
asymptomat
long
time
like
produc
neutral
antibodi
comparison
aid
patient
suggest
neutral
antibodi
serum
longterm
nonprogressor
may
contribut
control
viral
load
howev
hypothesi
question
polyclon
serum
screen
rpl
use
first
time
scala
et
al
screen
linear
constrain
rpl
vaccin
select
inovirus
mice
led
product
neutral
antibodi
year
later
rodriguez
et
al
use
polyclon
serum
screen
constrain
rpl
vaccin
mice
induc
product
antibodi
could
bind
inform
provid
neutral
potenc
addit
humbert
et
al
use
polyclon
serum
screen
constrain
rpl
vaccin
select
recombin
inovirus
mice
induc
product
neutral
antibodi
screen
rpl
use
polyclon
serum
monkey
infect
simianhuman
immunodefici
viru
shiv
perform
group
studi
vaccin
mice
perform
use
primeboost
strategi
dna
vaccin
prime
encod
cocktail
recombin
inovirus
boost
result
induct
neutral
antibodi
gazarian
et
al
screen
linear
constrain
rpl
use
sera
hivinfect
individu
vaccin
rabbit
result
product
antibodi
bind
nonhuman
primat
use
chen
et
al
anim
model
vaccin
recombin
inovirus
group
perform
screen
constrain
rpl
polyclon
serum
isol
infect
donor
vaccin
select
inovirus
perform
rhesu
macaqu
result
sera
vaccin
macaqu
exhibit
neutral
activ
furthermor
vaccin
macaqu
protect
infect
four
five
anim
abl
control
viral
load
challeng
pathogen
viru
import
result
underlin
potenti
method
addit
specif
ctl
respons
detect
impli
control
viral
load
exclus
result
humor
respons
sinc
first
attempt
induc
product
neutral
antibodi
use
inovirusbas
vaccin
effort
date
led
product
broadli
neutral
antibodi
vaccin
anim
failur
could
certain
extent
explain
usag
old
gener
monoclon
antibodi
shown
demonstr
autoreact
properti
vitro
studi
verkoczi
et
al
demonstart
vivo
studi
preb
cell
express
antibodi
unabl
matur
mice
suggest
trigger
immunolog
toler
due
autoreact
properti
antibodi
collect
studi
impli
screen
rpl
use
could
result
inoviralbas
vaccin
could
trigger
immunolog
toler
vaccin
anim
import
note
howev
lack
autoreact
properti
sever
next
gener
broadli
neutral
antibodi
could
solv
autoreact
problem
encount
despit
fact
recent
isol
new
broadli
neutral
antibodi
focus
attent
vaccin
develop
induct
humor
respons
recent
result
underlin
import
cellular
respons
well
experiment
result
concern
inovirusbas
vaccin
diseas
prove
inovirus
also
induc
strong
specif
cellular
respons
tabl
properti
make
great
candid
vector
vaccin
design
abil
inovirus
induc
cellular
immun
respons
first
demonstr
deberardini
et
al
work
recombin
inovirus
carri
epitop
epitop
revers
transcriptas
could
induc
specif
cellular
respons
human
cell
line
vitro
mice
vivo
peptid
interest
without
epitop
cellular
respons
undetect
indic
ctl
epitop
necessari
cellular
respons
possibl
enabl
intern
recombin
inoviru
apc
therefor
question
aris
whether
epitop
fuse
surfac
inoviru
induc
cellular
humor
respons
suggest
type
immun
respons
caus
epitop
fuse
surfac
inoviru
depend
length
sequenc
peptid
gaubin
et
al
demonstr
fitclabel
fd
virion
intern
human
ebvb
cell
line
fd
virion
success
degrad
target
mhc
class
class
ii
antigenprocess
pathway
confirm
endocellular
local
label
virion
confoc
microscopi
experi
show
inovirus
could
intern
apc
even
without
carri
ctl
epitop
low
rate
vivo
experi
howev
possibl
requir
ctl
epitop
critic
induct
cellular
respons
sartoriu
et
al
show
hybrid
fd
virion
scfv
antibodi
fragment
fuse
antigen
epitop
fuse
intern
human
dendrit
cell
specif
interact
scfv
receptor
addit
inocul
mice
hybrid
virion
induc
specif
cellular
respons
epitop
import
characterist
inovir
vector
induc
cellular
respons
report
two
studi
aim
develop
inovir
vaccin
possibl
due
complex
detect
cellular
respons
also
labor
intens
timeconsum
process
chen
et
al
attempt
detect
cellular
respons
respons
induc
experi
recent
research
studi
relat
clearli
demonstr
abil
inovirus
induc
strong
cellular
respons
perform
pedrozaroldan
et
al
effort
immunodomin
ctl
epitop
loop
residu
express
fusion
inoviru
random
peptid
librari
creat
insert
mutat
certain
posit
epitop
cocktail
inovirus
carri
loop
epitop
variat
epitop
use
vaccin
mice
result
ctl
respons
induc
import
result
studi
immun
induc
longlast
memori
tcell
respons
detect
seven
month
singl
immun
vaccin
also
induc
strong
humor
respons
sinc
sera
vaccin
mice
could
neutral
five
ten
pseudovirus
panel
experi
clearli
show
inovirus
capabl
induc
specif
cellular
immun
respons
abil
inovir
vector
induc
arm
adapt
immun
uniqu
could
prove
valuabl
develop
success
vaccin
gener
field
vaccin
design
studi
product
broadli
neutral
antibodi
vaccin
either
solubl
peptid
viral
vector
unsuccess
reason
effort
direct
induct
cellular
immun
respons
recent
year
vaccin
phase
phase
ii
clinic
trial
adenovir
vector
use
order
induc
cellular
immun
respons
vaccin
individu
howev
concern
safeti
virus
largescal
phase
iib
merck
trial
abruptli
termin
evid
individu
vaccin
adenoviru
vector
express
gag
pol
nef
becam
vulner
infect
comparison
control
suggest
group
increas
risk
infect
consist
individu
seroposit
eukaryot
virus
infect
speci
replic
human
cell
also
test
candid
hiv
vaccin
carrier
theori
safer
exampl
canarypox
vector
use
phase
iii
clinic
trial
clinic
trial
posit
result
date
offer
partial
protect
vaccin
individu
comparison
control
apart
safeti
reason
use
adenovirusbas
vector
protect
recent
hvtv
phase
iib
trial
use
adenoviru
boost
dna
prime
vaccin
human
volunt
abandon
futil
recent
rhesu
macaqu
cytomegaloviru
rhcmv
vector
success
induc
persist
ctl
respons
rhesu
macaqu
strongli
protect
vaccin
anim
challeng
pathogen
strain
importantli
studi
vaccin
anim
reduc
viral
load
undetect
level
howev
design
human
version
cmv
vector
could
impos
safeti
risk
sinc
human
cmv
persist
pathogen
human
viru
therefor
variou
type
eukaryot
viral
vector
current
investig
review
elsewher
howev
use
eukaryot
viru
accompani
seriou
safeti
concern
altern
use
prokaryot
virus
inovirus
may
util
decis
lower
safeti
risk
human
even
inovirus
could
infect
eukaryot
cell
assembl
new
prokaryot
virion
take
place
without
specif
condit
exist
intermembran
area
e
coli
without
presenc
specif
e
coli
enzym
leader
peptidas
exist
human
cell
furthermor
phase
case
studi
fd
inovirus
intraven
infus
human
purpos
unrel
vaccin
caus
side
effect
even
allerg
reaction
eight
volunt
knowledg
case
inovirus
infus
human
therefor
contrast
viral
vector
use
inovirus
impos
major
safeti
risk
human
characterist
inovir
vector
along
capabl
trigger
cellular
humor
immun
respons
make
attract
option
vaccin
vector
last
two
decad
inovir
vector
use
develop
vaccin
variou
infecti
parasit
noninfecti
diseas
like
cancer
alzheim
promis
result
applic
inoviru
display
technolog
vaccin
design
diseas
mostli
success
design
vaccin
develop
far
disappoint
major
obstacl
use
neutral
monoclon
antibodi
plagu
autoreact
properti
screen
rpl
antibodi
result
isol
peptid
vaccin
antigen
unsuccess
induc
specif
humor
respons
would
produc
neutral
antibodi
recent
isol
antibodi
neutral
breadth
potenc
without
autoreact
properti
previous
util
antibodi
may
overcom
obstacl
particularli
induct
antibodi
could
feasibl
target
sinc
antibodi
also
seem
produc
signific
percentag
popul
humor
respons
well
document
cellular
respons
assess
studi
design
vaccin
use
inovirus
studi
cellular
respons
detect
also
report
success
induct
longlast
memori
ctl
respons
seven
month
singl
vaccin
mice
inovir
particl
demonstr
induct
cellular
immun
use
inovirus
feasibl
iav
advantag
induc
arm
adapt
immun
find
could
therefor
import
futur
effort
design
vaccin
moreov
iav
uniqu
characterist
compar
viral
vector
stabl
display
peptid
multipl
thousand
copi
surfac
construct
immunogen
without
use
adjuv
addit
iav
allow
immun
system
focu
specif
epitop
interest
instead
whole
protein
great
import
sinc
import
aspect
success
vaccin
design
focu
induct
neutral
antibodi
specif
neutral
epitop
time
avoid
induct
ineffect
antibodi
numer
nonneutr
epitop
glycoprotein
act
decoy
immun
system
ideal
effect
vaccin
abl
stimul
humor
cellular
immun
respons
recent
adenovir
vector
test
clinic
trial
vaccin
carrier
order
induc
cellular
immun
shown
impos
seriou
health
risk
human
hand
iav
abl
induc
cellular
immun
time
demonstr
safe
administr
anim
human
characterist
iav
confer
structur
biolog
properti
make
effect
antigen
display
vector
induc
strong
specif
humor
cellular
immun
respons
display
antigen
properti
iav
along
newli
discov
broadli
neutral
antibodi
pave
way
develop
effect
vaccin
